ClinicalTrials.govpublic full text
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
hepatocellular carcinoma
ClinicalTrials.gov
Show glossary
Search for terms
Hide glossary
Study record managers: refer to the
Data Element Definitions
if submitting registration or results information.
Record · ID 28320 · SHA-256 17c3746fc8cd5ac2
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.